DRGEM Corporation (263690) Fair Value & Analysis
Healthcare · KR · Market cap 53.2B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price +1.6% over the past month.
A solid business, screening 164% undervalued on our models.
What matters now
- The price is below even our cautious bear case (9,186 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (9,186 KRW to 17,110 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 4,750 KRW – 14,269 KRW · fair‑value band 9,186 KRW – 17,110 KRW · the 5,190 KRW price screens below the 13,688 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
DRGEM Corporation (263690) currently trades at 5,190 KRW, while our model-based Fair Value estimate is 13,688 KRW, implying the stock looks roughly 163.8% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, DRGEM Corporation generated revenue of 107B KRW at a net margin of 9.0%. Revenue grew 17.1% year over year. It earns a return on equity of 10.7%. Fundamentals as of Jul 20, 2026
Our scenario range runs from 9,186 KRW (bear case) to 17,110 KRW (bull case); at 5,190 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at 164%, 263690 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (12,255 KRW) versus Earnings-Based (4,237 KRW). Highest evidence: Growth DCF (80).
Notify me when 263690 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
DRGEM Corporation manufactures and sells diagnostic radiography systems. It offers high frequency X-ray generators; conventional and digital radiography systems; and ACQUIDR, a digital imaging system. DRGEM Corporation exports its products. The company was founded in 2003 and is headquartered in Gwangmyeong-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DRGEM Corporation reported revenue of 103B KRW in FY2025 versus 85.8B KRW in FY2021, a compound +4.6%/yr. Reported net income was 6.8B KRW in FY2025, compounding −14.3%/yr from FY2021.
Watch 263690: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare DRGEM Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DRGEM Corporation (263690) overvalued or undervalued?
What is the fair value of 263690?
What is the quality score of 263690?
What is the revenue of DRGEM Corporation (263690)?
What is the net profit margin of 263690?
Does DRGEM Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DRGEM Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.